Astria Therapeutics’ (ATXS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report released on Friday, Benzinga reports. HC Wainwright currently has a $16.00 target price on the biotechnology company’s stock.

A number of other equities research analysts also recently commented on the company. Wedbush reissued an outperform rating and issued a $22.00 target price on shares of Astria Therapeutics in a report on Friday. Jefferies Financial Group raised their target price on Astria Therapeutics from $22.00 to $27.00 and gave the company a buy rating in a report on Monday, March 25th.

Astria Therapeutics Stock Performance

NASDAQ:ATXS traded down $0.44 during midday trading on Friday, reaching $9.73. The stock had a trading volume of 443,655 shares, compared to its average volume of 824,755. The firm has a fifty day simple moving average of $12.16 and a two-hundred day simple moving average of $9.54. Astria Therapeutics has a 12-month low of $4.26 and a 12-month high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). On average, sell-side analysts expect that Astria Therapeutics will post -1.55 EPS for the current year.

Institutional Investors Weigh In On Astria Therapeutics

Large investors have recently bought and sold shares of the stock. AJOVista LLC purchased a new stake in shares of Astria Therapeutics in the fourth quarter valued at $51,000. Jump Financial LLC acquired a new position in Astria Therapeutics in the 3rd quarter valued at about $111,000. Panagora Asset Management Inc. purchased a new position in Astria Therapeutics in the 4th quarter valued at about $119,000. Trexquant Investment LP acquired a new stake in shares of Astria Therapeutics during the 4th quarter worth about $409,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Astria Therapeutics during the fourth quarter worth about $1,469,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.